Document is current
Any future updates will be listed below
-
Authors
Luxen, Matthijs https://orcid.org/0000-0002-0685-3894
van der Aart, Tamar J. https://orcid.org/0000-0002-1518-8603
Jongman, Rianne M. https://orcid.org/0000-0002-7521-9096
Zwiers, Peter J. https://orcid.org/0000-0002-6493-1897
Moser, Jill https://orcid.org/0000-0002-9614-2577
Pultar, Marianne
Skalicky, Susanna
Diendorfer, Andreas B. https://orcid.org/0000-0003-0331-9685
Bouma, Hjalmar R. https://orcid.org/0000-0003-1032-321X
Koeze, Jacqueline https://orcid.org/0000-0002-4660-3400
Hackl, Matthias https://orcid.org/0000-0002-4136-7293
Molema, Grietje https://orcid.org/0000-0002-4147-6676
van Meurs, Matijs https://orcid.org/0000-0002-7745-2772
-
Funding
Funding for this research was provided by:
Stichting De Cock-Hadders (2021-66)
Health~Holland (6334, 6334)
- License Information
-
More Information
Article History
Received: 17 January 2025
Accepted: 22 August 2025
First Online: 2 October 2025
Competing interests
: M. Hackl is co-founder and CEO/CSO of TAmiRNA GmbH, which provides small RNA sequencing and RNA sequencing analysis services. A. B. Diendorfer, M. Pultar, and S. Skalicky are employed by TAmiRNA. G. Molema is co-founder and CSO/CTO of Vivomicx BV, which provides laser microdissection analysis services. Vivomicx and TAmiRNA contributed financially to the PPP allowance. The remaining authors declare no conflicts of interest. All authors have read the journal’s authorship agreement, and the manuscript has been reviewed and approved by all authors.
